A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease.

摘要: The immunologic and virologic activity of nevirapine in combination with two nucleosides (zidovudine [ZDV] didanosine [ddI]) was evaluated antiretroviral-naive patients a CD4 count <200/mm3 or clinical AIDS. In all, 68 were enrolled 48-week double-blind, placebo-controlled trial. A group 32 received ZDV + ddI nevirapine, 36 ddI. Primary efficacy parameters the on HIV-1 RNA peripheral blood CD4+ cells, differences between groups analyzed by Wilcoxon's nonparametric two-sample test. Baseline high both treatment (median values, 5.8 5.7 log10). responses significantly higher triple reductions, 2.69 versus 1.05 log10 at 24 weeks 1.97 1.20 48 weeks; median increases, 81 64 cells/mm3 101 27 weeks). This study demonstrates that used as first-line regimen can induce sustained response low previous diagnosis